What Is Progressive Pulmonary Fibrosis (PPF) in ILD?

It is completely understandable to feel confused or worried when a doctor uses a new term like “progressive pulmonary fibrosis” (PPF), especially when you have already been diagnosed with a condition like rheumatoid arthritis-ILD or hypersensitivity pneumonitis.

Progressive pulmonary fibrosis (PPF) is not a new disease that replaces your original diagnosis. Instead, it is a clinical term used to describe how your interstitial lung disease (ILD) is behaving ^[1][2]. It means that the scarring (fibrosis) in your lungs has actively worsened over the past year.

Because PPF is a behavioral description (often called a “progressive phenotype”), your initial diagnosis remains unchanged ^[1]. Recognizing that your disease is progressing simply helps your care team reassess your treatment plan and closely monitor your lung health.

How Doctors Identify PPF

To classify your ILD as progressive, doctors look for specific signs that your condition is actively worsening. According to medical guidelines, your doctor must first rule out other reasons for your decline—such as an infection, heart disease, anemia, or ongoing environmental exposures (like mold or birds) ^[1].

Once other causes are ruled out, clinicians generally look for worsening in at least two of the following three areas within the past year ^[1][3]:

1. Worsening Symptoms: A noticeable increase in respiratory symptoms, such as a worsening chronic cough or feeling more short of breath during daily activities.
2. Declining Lung Function: A drop in your pulmonary function test (PFT) numbers. Doctors look for an absolute decline in your Forced Vital Capacity (FVC) (how much air you can forcefully exhale) of at least 5%, or a decline in your DLCO (a measure of how well oxygen passes from your lungs into your blood) of at least 10% ^[1].
3. Changes on Imaging: A High-Resolution CT (HRCT) scan showing that visible scar tissue in your lungs has spread or become more severe compared to previous scans ^[1][3].

What PPF Does and Does Not Mean

• It DOES mean your care team will want to discuss your current management. They will evaluate if your underlying disease treatment (like immunosuppressants or antigen avoidance) needs to be optimized, or if new medications should be considered ^[1].
• It DOES NOT mean your original diagnosis was wrong or that your medical team is abandoning treatment for your underlying condition ^[1].
• It DOES NOT mean immediate respiratory failure or provide an exact timeline. PPF indicates a higher risk of ongoing progression, but the rate of change is different for every individual.

Discussing New Treatment Options

When your disease is classified as PPF, it often prompts a discussion about adding an antifibrotic medication (such as nintedanib) to your treatment plan. Antifibrotics are designed specifically to target lung scarring.

What to Know About Antifibrotics

• Slowing the decline: In clinical trials for progressive fibrosing ILDs, antifibrotic medications have been shown to slow down the average annual loss of lung function (FVC decline) compared to a placebo ^[4][5].
• They are not a cure: It is vital to understand that antifibrotics do not reverse or heal existing scar tissue, nor do they guarantee your symptoms will dramatically improve ^[6]. Their goal is to protect your remaining lung function.
• Side effects and safety: Antifibrotics require careful monitoring. The most common side effects involve the digestive system, particularly diarrhea and nausea, which can sometimes be severe and lead to dehydration ^[7][8]. Nintedanib can also cause elevated liver enzymes, so you will need baseline and regular follow-up blood tests to monitor your liver health. Your doctor will also consider any bleeding risks, medication interactions (like blood thinners), and pregnancy risks before prescribing it.

Adding an antifibrotic is not an automatic or mandatory step. The decision is highly individualized. Your specialist will weigh your underlying ILD, the pattern of your progression, your current medications, your liver function, and your personal preferences before recommending a change in therapy. Always contact your care team immediately if you experience severe diarrhea, jaundice, unusual bleeding, or sudden severe breathlessness while on these medications—do not change doses or stop treatments on your own without medical guidance.